Comparative Pharmacology
Head-to-head clinical analysis: BKEMV versus CIDOFOVIR.
Head-to-head clinical analysis: BKEMV versus CIDOFOVIR.
BKEMV vs CIDOFOVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BKEMV is a monoclonal antibody that binds to the extracellular domain of the HER2/neu receptor, inhibiting downstream signaling pathways including PI3K/Akt and MAPK, thereby reducing cell proliferation and promoting antibody-dependent cell-mediated cytotoxicity (ADCC).
Cidofovir is a nucleotide analog that inhibits viral DNA polymerase by competing with deoxycytidine triphosphate for incorporation into viral DNA, resulting in chain termination and inhibition of viral replication.
Intravenous: 100 mg every 12 hours; oral: 50 mg twice daily.
5 mg/kg intravenously once weekly for 2 weeks, then 5 mg/kg every 2 weeks. Administer with probenecid 2 g orally 3 hours before dose, then 1 g at 2 and 8 hours after dose. Hydrate with 1 L normal saline before infusion.
None Documented
None Documented
Clinical Note
moderateCidofovir + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cidofovir."
Clinical Note
moderateTenofovir disoproxil + Cidofovir
"Tenofovir disoproxil may decrease the excretion rate of Cidofovir which could result in a higher serum level."
Terminal elimination half-life: 12-18 hours in healthy adults; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Terminal elimination half-life is approximately 2.5 hours. However, the intracellular half-life of the active diphosphate metabolite is >48 hours, supporting once-weekly dosing.
Renal excretion: 40-50% unchanged; biliary/fecal: 20-30% as metabolites; total clearance approximates renal clearance.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for approximately 90% of the administered dose. Biliary/fecal elimination is minimal (<5%).
Category C
Category D/X
Antiviral, HIV
Antiviral